Skip to content
DataLookout
Menu

Dapa-Active LNNCT07323524

Dapagliflozin in Active Lupus Nephritis

StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion moved earlier from Jul 2029 to Jul 1, 2028 Show 5 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Study completion moved earlier from Jan 2030 to Sep 1, 2028
    • Start date: May 19, 2026 to May 22, 2026
    • Site details revised at 1 of 2 sites
    • Study description expanded, about 4 words
  2. Notable Recruitment opened
    • Start date changed from estimate of Jun 1, 2026 to May 19, 2026
    • Site details revised at 2 of 2 sites
    v5
  3. Notable Start date: Feb 1, 2026 to Jun 1, 2026v4
  4. Minor Study sites: 0 to 2v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of eligible enrolled
Timeframe: 3 years

Secondary (1)

Feasibility of data collection

Arms and interventions

Dapagliflozin 10 mg dailyActive comparator

Subjects will receive masked dapagliflozin 10 mg daily for 12 weeks

Matching placebo pill dailyPlacebo comparator

Subjects will receive a matching placebo pill to take daily for 12 weeks

Drugs: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo

Sites

2 sites in 1 country